Large-Scale Rapid Production, Increased Bioavailability
MOUNTAIN VIEW, Calif., Oct. 21 /PRNewswire/ -- An increased number of diseases that are either incurable or difficult to treat allures clinicians to the approach of stem cell therapy. Highly prized, due to their therapeutic potential, stem cell therapies are believed to treat a wide variety of diseases. Stem cell research progresses at a fast pace; however, both adult and embryonic stem cells have their own unique challenges that must be overcome before therapies make it to the market.
New analysis from Frost & Sullivan (http://www.pharmaceuticals.frost.com), U.S. Stem Cell Market - Current Developments, provides insights and analysis on stem cell therapeutic development in the U.S., including the clinical trial pipeline, key market drivers and challenges, and the market potential for stem cell therapy in selected disease indications. In this research, Frost & Sullivan's expert analysts thoroughly examine this cutting-edge healthcare technology market.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of U.S. Stem Cell Market - Current Developments, please send an e-mail to Johanna Haynes, Corporate Communications, at email@example.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.
"New research into stem cell therapies has resulted in several
technological innovations that have improved the manufacturing and design
of these products," notes Frost & Sullivan Research Analyst Katheryn
Symank. "For example, improvements in cell sorting and cell culture have
allowed for improved survival and growth of adult stem cel
|SOURCE Frost & Sullivan|
Copyright©2008 PR Newswire.
All rights reserved